Quick Answer
Harmony Biosciences Holdings, Inc. reported Research And Development Expense of $189.59 million for the year ending 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +30.0% in Research And Development Expense from 2024 to 2025.
- This data is from Harmony Biosciences Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $4.34 million | Q1 2020: $3.43 million | Q2 2020: $4.17 million | Q3 2020: $4.23 million | Q1 2021: $4.68 million | Q2 2021: $6.50 million | Q3 2021: $11.74 million | Q1 2022: $7.58 million | Q2 2022: $12.67 million | Q3 2022: $40.55 million | Q1 2023: $13.29 million | Q2 2023: $14.97 million | Q3 2023: $17.50 million | Q1 2024: $22.19 million | Q2 2024: $63.58 million | Q3 2024: $25.39 million | Q1 2025: $34.54 million | Q2 2025: $50.16 million | Q3 2025: $54.96 million.
- Over the full 7 years of available data (2019 to 2025), Harmony Biosciences Holdings, Inc.'s Research And Development Expense has grown by 172.4%.
- Historical annual values: Fiscal year 2025: $189.59 million | Fiscal year 2024: $145.83 million | Fiscal year 2023: $76.06 million | Fiscal year 2022: $70.89 million | Fiscal year 2021: $30.37 million | Fiscal year 2020: $19.45 million | Fiscal year 2019: $69.60 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: